



international excipients
certification



NEWS RELEASE

MEGGLE SITE RECEIVES EXCiPACT™ CERTIFICATION AS PHARMACEUTICAL EXCIPIENT SUPPLIERS

Brussels, 25th September, 2014:

EXCiPACT asbl is delighted to announce that **Molkerei MEGGLE Wasserburg GmbH & Co. KG** has recently received an EXCiPACT™ Certificate from SGS France, one of EXCiPACT's internationally-recognised Certification Bodies.

The Certificate demonstrates that the MEGGLE site at Wasserburg, Germany manufactures and distributes pharmaceutical excipients according to the EXCiPACT™ Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certification Standards.

The Wasserburg site is the seventh German site to receive Certification and is the 13th site to be Certified globally to date. The others sites are in Belgium, Canada, France, The Netherlands, Spain and Saudi Arabia - see <http://www.excipact.org/certification/certificates/>

Both SGS and their auditors had to undergo a rigorous assessment process in order to be EXCiPACT™ Registered. This required the successful completion of the formal EXCiPACT™ Training Programme and Examination and an independently witnessed audit to verify that their competency was at the required standard.

EU and U.S. pharmaceutical excipient regulations now require drug manufacturers to do either their own or 3rd party physical audits of all their starting material suppliers to demonstrate GMP and/or GDP compliance. The audit burden is huge. Using GMP and GDP standards designed for excipients, the new, high quality 3rd Party EXCiPACT™ Certification Scheme is already helping excipient users and suppliers to reduce their audit burden, save costs and ensure quality.

Notes for the Editor

EXCiPACT asbl provides management oversight for a high quality, voluntary international scheme that provides for independent 3rd party certification of manufacturers, suppliers and distributors of pharmaceutical excipients worldwide. The Scheme will ensure patient safety through supplier quality while minimising the overall costs for assessing the excipient supply chain. It was launched in January 2012 since when there has been considerable interest among pharmaceutical excipient suppliers, customers and regulators. For further information see www.excipact.org or contact info@excipact.org.

minimize risks, maximize benefits

info@excipact.org
www.excipact.org